Beta-Blocker study reveals how heart pumps better

NCT ID NCT01261065

Completed Knowledge-focused Sponsor: Michael E. DeBakey VA Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how the beta-blocker carvedilol helps the heart pump better in people with heart failure. Fifty-five patients with weak hearts took the highest tolerated dose for six months. Researchers measured changes in heart muscle contraction to understand the underlying improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carvedilol (a beta-blocker drug, also known as Coreg)
What this could lead to: If successful, this could help doctors understand exactly how beta-blockers improve heart pumping in heart failure, potentially leading to better treatment strategies.
What could go wrong: This is a small, completed study focused on understanding mechanisms, not testing a new treatment. Results may not apply to all heart failure patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy dilated cardiomyopathy heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOMYOPATHY HEART FAILURE

Contacts and locations

Locations

Michael E. DeBakey Veterans Affairs Medical Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.